News | November 25, 2023
Laurus Labs acquires 87.59% stake in Laurus Bio Private
Laurus Labs concluded the acquisition by securing the remaining 8,333 equity shares from the promoter group shareholders
Laurus Labs concluded the acquisition by securing the remaining 8,333 equity shares from the promoter group shareholders
Jan Ausahdhi exhibited demonstration stall during 42nd India International Trade Fair to spread awareness
Distributes Ayushman cards to several beneficiaries
Evinova will operate as a separate health-tech business within AstraZeneca
Decision on EU marketing authorisation expected for momelotinib by early 2024
Emphasizes the need for a collective effort on bolstering resilience across economies, societies, healthcare systems, education systems and infrastructure
Approval based on results from the Phase 3 KEYNOTE-859 trial, which demonstrated significant improvement in overall survival in these patients versus chemotherapy alone
Phase 3 data expected in the second half of 2024
Reports revenue growth of 9% to INR 882 crores in Q2 FY24
EBITDA for Q2 FY24 at Rs. 71.2 crore as compared to Rs. 79.9 crore QoQ
Subscribe To Our Newsletter & Stay Updated
